{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:23:40Z","timestamp":1785018220501,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Social Development Project of Jiangsu Province Science and Technology Plan","award":["BE2023775"],"award-info":[{"award-number":["BE2023775"]}]},{"name":"Clinical Capacity Enhancement Project","award":["JSPH-MC-2023-6"],"award-info":[{"award-number":["JSPH-MC-2023-6"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06847-y","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T01:11:41Z","timestamp":1769735501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hemophagocytic lymphohistiocytosis associated with extranodal NK\/T cell lymphoma, nasal type or aggressive NK cell leukemia: a retrospective multicenter study of Jiangsu Cooperative Lymphoma Group (JCLG)"],"prefix":"10.1007","volume":"105","author":[{"given":"Yongle","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwen","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiudan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"6847_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMra2314005","volume":"392","author":"JI Henter","year":"2025","unstructured":"Henter JI (2025) Hemophagocytic lymphohistiocytosis. N Engl J Med 392:584\u2013598. https:\/\/doi.org\/10.1056\/NEJMra2314005","journal-title":"N Engl J Med"},{"key":"6847_CR2","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1182\/bloodadvances.2024014715","volume":"9","author":"X Shu","year":"2025","unstructured":"Shu X, Gao X, Dai Y et al (2025) C3 as a predictive and prognostic biomarker in adult hemophagocytic lymphohistiocytosis: a large cohort study in China. Blood Adv 9:1836\u20131846. https:\/\/doi.org\/10.1182\/bloodadvances.2024014715","journal-title":"Blood Adv"},{"key":"6847_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1586\/ehm.10.51","volume":"3","author":"F Ishida","year":"2010","unstructured":"Ishida F, Kwong YL (2010) Diagnosis and management of natural killer-cell malignancies. Expert Rev Hematol 3:593\u2013602. https:\/\/doi.org\/10.1586\/ehm.10.51","journal-title":"Expert Rev Hematol"},{"key":"6847_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.canep.2016.02.007","volume":"42","author":"BA Bassig","year":"2016","unstructured":"Bassig BA, Au WY, Mang O et al (2016) Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the united States, 2001\u20132010. Cancer Epidemiol 42:15\u201323. https:\/\/doi.org\/10.1016\/j.canep.2016.02.007","journal-title":"Cancer Epidemiol"},{"issue":"Suppl 1","key":"6847_CR5","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1517\/14728222.2011.621418","volume":"16","author":"YL Kwong","year":"2012","unstructured":"Kwong YL (2012) Pathogenesis and treatment of leukemia: an Asian perspective. Expert Opin Ther Targets 16(Suppl 1):S37\u201343. https:\/\/doi.org\/10.1517\/14728222.2011.621418","journal-title":"Expert Opin Ther Targets"},{"key":"6847_CR6","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/modpathol.2017.37","volume":"30","author":"J Gao","year":"2017","unstructured":"Gao J, Behdad A, Ji P et al (2017) EBV-negative aggressive NK-cell leukemia\/lymphoma: a clinical and pathological study from a single institution. Mod Pathol 30:1100\u20131115. https:\/\/doi.org\/10.1038\/modpathol.2017.37","journal-title":"Mod Pathol"},{"key":"6847_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.humpath.2020.08.008","volume":"105","author":"J Gao","year":"2020","unstructured":"Gao J, Zhang Y, Yaseen NR et al (2020) Comprehensive molecular genetic studies of Epstein-Barr virus-negative aggressive natural killer-cell leukemia\/lymphoma. Hum Pathol 105:20\u201330. https:\/\/doi.org\/10.1016\/j.humpath.2020.08.008","journal-title":"Hum Pathol"},{"key":"6847_CR8","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","volume":"120","author":"YL Kwong","year":"2012","unstructured":"Kwong YL, Kim WS, Lim ST et al (2012) SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group. Blood 120:2973\u20132980. https:\/\/doi.org\/10.1182\/blood-2012-05-431460","journal-title":"Blood"},{"key":"6847_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/17474086.2021.1955345","volume":"14","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Lee D, Gesiotto Q et al (2021) Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies. Expert Rev Hematol 14:731\u2013740. https:\/\/doi.org\/10.1080\/17474086.2021.1955345","journal-title":"Expert Rev Hematol"},{"key":"6847_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41409-020-01009-8","volume":"56","author":"A Fujimoto","year":"2021","unstructured":"Fujimoto A, Ishida F, Izutsu K et al (2021) Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. Bone Marrow Transpl 56:347\u2013356. https:\/\/doi.org\/10.1038\/s41409-020-01009-8","journal-title":"Bone Marrow Transpl"},{"key":"6847_CR11","doi-asserted-by":"publisher","first-page":"e70178","DOI":"10.1002\/cam4.70178","volume":"13","author":"Y Miao","year":"2024","unstructured":"Miao Y, Zhang J, Lu X et al (2024) Clinicopathological characteristics, prognostic factors, and outcomes of elderly patients with lymphoma-associated hemophagocytic lymphohistiocytosis: A multicenter analysis. Cancer Med 13:e70178. https:\/\/doi.org\/10.1002\/cam4.70178","journal-title":"Cancer Med"},{"key":"6847_CR12","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00432-022-04147-2","volume":"149","author":"Y He","year":"2023","unstructured":"He Y, Gao Y, Ping L et al (2023) The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK\/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. J Cancer Res Clin Oncol 149:2017\u20132027. https:\/\/doi.org\/10.1007\/s00432-022-04147-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"6847_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1349-7006.2012.02251.x","volume":"103","author":"F Ishida","year":"2012","unstructured":"Ishida F, Ko YH, Kim WS et al (2012) Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci 103:1079\u20131083. https:\/\/doi.org\/10.1111\/j.1349-7006.2012.02251.x","journal-title":"Cancer Sci"},{"key":"6847_CR14","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00277-022-04953-1","volume":"101","author":"G Meng","year":"2022","unstructured":"Meng G, Wang J, Cui T et al (2022) Clinical characteristics and treatment of NK\/T-cell lymphoma-associated HLH. Ann Hematol 101:2289\u20132296. https:\/\/doi.org\/10.1007\/s00277-022-04953-1","journal-title":"Ann Hematol"},{"key":"6847_CR15","doi-asserted-by":"publisher","unstructured":"Yoshimori M, Nishio M, Ohashi A et al (2021) Interferon-\u03b3 produced by EBV-positive neoplastic NK-Cells induces differentiation into macrophages and procoagulant activity of monocytes, which leads to HLH. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13205097","DOI":"10.3390\/cancers13205097"},{"key":"6847_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124\u2013131. https:\/\/doi.org\/10.1002\/pbc.21039","journal-title":"Pediatr Blood Cancer"},{"key":"6847_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.23911","volume":"90","author":"ZK Otrock","year":"2015","unstructured":"Otrock ZK, Eby CS (2015) Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 90:220\u2013224. https:\/\/doi.org\/10.1002\/ajh.23911","journal-title":"Am J Hematol"},{"key":"6847_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/bf02982007","volume":"74","author":"N Takahashi","year":"2001","unstructured":"Takahashi N, Chubachi A, Kume M et al (2001) A clinical analysis of 52 adult patients with hemophagocytic syndrome: the prognostic significance of the underlying diseases. Int J Hematol 74:209\u2013213. https:\/\/doi.org\/10.1007\/bf02982007","journal-title":"Int J Hematol"},{"key":"6847_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41375-024-02135-8","volume":"38","author":"J Knauft","year":"2024","unstructured":"Knauft J, Schenk T, Ernst T et al (2024) Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia 38:235\u2013249. https:\/\/doi.org\/10.1038\/s41375-024-02135-8","journal-title":"Leukemia"},{"key":"6847_CR20","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.3324\/haematol.2019.220301","volume":"105","author":"JH Liang","year":"2020","unstructured":"Liang JH, Wang L, Zhu HY et al (2020) Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial. Haematologica 105:e29\u2013e32. https:\/\/doi.org\/10.3324\/haematol.2019.220301","journal-title":"Haematologica"},{"key":"6847_CR21","doi-asserted-by":"publisher","unstructured":"El Hussein S, Medeiros LJ, Khoury JD (2020) Aggressive NK cell leukemia: current state of the Art. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12102900","DOI":"10.3390\/cancers12102900"},{"key":"6847_CR22","first-page":"1343","volume":"87","author":"SY Song","year":"2002","unstructured":"Song SY, Kim WS, Ko YH et al (2002) Aggressive natural killer cell leukemia: clinical features and treatment outcome. Haematologica 87:1343\u20131345","journal-title":"Haematologica"},{"key":"6847_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.trsl.2014.01.010","volume":"163","author":"C Li","year":"2014","unstructured":"Li C, Tian Y, Wang J et al (2014) Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de Novo aggressive natural killer cell leukemia. Transl Res 163:565\u2013577. https:\/\/doi.org\/10.1016\/j.trsl.2014.01.010","journal-title":"Transl Res"},{"key":"6847_CR24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/15384047.2017.1295176","volume":"18","author":"N Li","year":"2017","unstructured":"Li N, Zhang L, Liu J et al (2017) A clinical study of 21 patients with hemophagocytic syndrome in 295 cases diagnosed with nasal type, extranodal nature killer\/T cell lymphoma. Cancer Biol Ther 18:252\u2013256. https:\/\/doi.org\/10.1080\/15384047.2017.1295176","journal-title":"Cancer Biol Ther"},{"key":"6847_CR25","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00277-016-2805-9","volume":"95","author":"J Jia","year":"2016","unstructured":"Jia J, Song Y, Lin N et al (2016) Clinical features and survival of extranodal natural killer\/T cell lymphoma with and without hemophagocytic syndrome. Ann Hematol 95:2023\u20132031. https:\/\/doi.org\/10.1007\/s00277-016-2805-9","journal-title":"Ann Hematol"},{"key":"6847_CR26","doi-asserted-by":"publisher","first-page":"970183","DOI":"10.3389\/fimmu.2022.970183","volume":"13","author":"Y Miao","year":"2022","unstructured":"Miao Y, Zhang J, Chen Q et al (2022) Spectrum and trigger identification of hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 555 cases. Front Immunol 13:970183. https:\/\/doi.org\/10.3389\/fimmu.2022.970183","journal-title":"Front Immunol"},{"key":"6847_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hon.2998","volume":"40","author":"M Zheng","year":"2022","unstructured":"Zheng M, Bao Y, Wang J et al (2022) The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases. Hematol Oncol 40:381\u2013389. https:\/\/doi.org\/10.1002\/hon.2998","journal-title":"Hematol Oncol"},{"key":"6847_CR28","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s10875-023-01493-9","volume":"43","author":"J Zhang","year":"2023","unstructured":"Zhang J, Qin S, Jin Z et al (2023) The clinical significance and prognostic role of Whole-Blood Epstein-Barr virus DNA in Lymphoma-Associated hemophagocytic lymphohistiocytosis. J Clin Immunol 43:1302\u20131310. https:\/\/doi.org\/10.1007\/s10875-023-01493-9","journal-title":"J Clin Immunol"},{"key":"6847_CR29","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3109\/10428194.2013.876629","volume":"55","author":"L Han","year":"2014","unstructured":"Han L, Li L, Wu J et al (2014) Clinical features and treatment of natural killer\/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome. Leuk Lymphoma 55:2048\u20132055. https:\/\/doi.org\/10.3109\/10428194.2013.876629","journal-title":"Leuk Lymphoma"},{"key":"6847_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fonc.2019.00386","volume":"9","author":"Q Cai","year":"2019","unstructured":"Cai Q, Cai J, Fang Y et al (2019) Epstein-Barr Virus-Positive natural Killer\/T-Cell lymphoma. Front Oncol 9:386. https:\/\/doi.org\/10.3389\/fonc.2019.00386","journal-title":"Front Oncol"},{"key":"6847_CR31","doi-asserted-by":"publisher","unstructured":"Sausen DG, Basith A, Muqeemuddin S (2023) EBV and lymphomagenesis. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15072133","DOI":"10.3390\/cancers15072133"},{"key":"6847_CR32","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jaci.2024.11.029","volume":"155","author":"M Liu","year":"2025","unstructured":"Liu M, Brodeur KE, Bledsoe JR et al (2025) Features of hyperinflammation link the biology of Epstein-Barr virus infection and cytokine storm syndromes. J Allergy Clin Immunol 155:1346\u20131356e1349. https:\/\/doi.org\/10.1016\/j.jaci.2024.11.029","journal-title":"J Allergy Clin Immunol"},{"key":"6847_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/jmv.1029","volume":"64","author":"I Tsuge","year":"2001","unstructured":"Tsuge I, Morishima T, Kimura H et al (2001) Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection. J Med Virol 64:141\u2013148. https:\/\/doi.org\/10.1002\/jmv.1029","journal-title":"J Med Virol"},{"key":"6847_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fped.2019.00071","volume":"7","author":"WY Kim","year":"2019","unstructured":"Kim WY, Montes-Mojarro IA, Fend F et al (2019) Epstein-Barr Virus-Associated T and NK-Cell lymphoproliferative diseases. Front Pediatr 7:71. https:\/\/doi.org\/10.3389\/fped.2019.00071","journal-title":"Front Pediatr"},{"key":"6847_CR35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/978-981-10-7230-7_21","volume":"1045","author":"H Kimura","year":"2018","unstructured":"Kimura H (2018) EBV in T-\/NK-Cell tumorigenesis. Adv Exp Med Biol 1045:459\u2013475. https:\/\/doi.org\/10.1007\/978-981-10-7230-7_21","journal-title":"Adv Exp Med Biol"},{"key":"6847_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fped.2019.00014","volume":"7","author":"A Arai","year":"2019","unstructured":"Arai A (2019) Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr 7:14. https:\/\/doi.org\/10.3389\/fped.2019.00014","journal-title":"Front Pediatr"},{"key":"6847_CR37","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/s2352-3026(21)00366-5","volume":"9","author":"A Setiadi","year":"2022","unstructured":"Setiadi A, Zoref-Lorenz A, Lee CY et al (2022) Malignancy-associated haemophagocytic lymphohistiocytosis. Lancet Haematol 9:e217\u2013e227. https:\/\/doi.org\/10.1016\/s2352-3026(21)00366-5","journal-title":"Lancet Haematol"},{"key":"6847_CR38","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Ros\u00e9e","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M et al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133:2465\u20132477. https:\/\/doi.org\/10.1182\/blood.2018894618","journal-title":"Blood"},{"key":"6847_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.blre.2016.05.001","volume":"30","author":"A Hayden","year":"2016","unstructured":"Hayden A, Park S, Giustini D et al (2016) Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. Blood Rev 30:411\u2013420. https:\/\/doi.org\/10.1016\/j.blre.2016.05.001","journal-title":"Blood Rev"},{"key":"6847_CR40","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood.2023022281","volume":"143","author":"S B\u00f6hm","year":"2024","unstructured":"B\u00f6hm S, Wustrau K, Pachlopnik Schmid J et al (2024) Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: Etoposide is better than its reputation. Blood 143:872\u2013881. https:\/\/doi.org\/10.1182\/blood.2023022281","journal-title":"Blood"},{"key":"6847_CR41","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/15384047.2021.1996139","volume":"22","author":"Y Song","year":"2021","unstructured":"Song Y, Wang J, Wang Y et al (2021) Requirement for containing Etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis. Cancer Biol Ther 22:598\u2013606. https:\/\/doi.org\/10.1080\/15384047.2021.1996139","journal-title":"Cancer Biol Ther"},{"key":"6847_CR42","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten E, Horne A, Aric\u00f3 M et al (2017) Confirmed efficacy of Etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 130:2728\u20132738. https:\/\/doi.org\/10.1182\/blood-2017-06-788349","journal-title":"Blood"},{"key":"6847_CR43","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1159\/000514920","volume":"144","author":"L Naymagon","year":"2021","unstructured":"Naymagon L, Tremblay D, Mascarenhas J (2021) The efficacy of Etoposide-Based therapy in adult secondary hemophagocytic lymphohistiocytosis. Acta Haematol 144:560\u2013568. https:\/\/doi.org\/10.1159\/000514920","journal-title":"Acta Haematol"},{"key":"6847_CR44","doi-asserted-by":"publisher","first-page":"e30122","DOI":"10.1002\/pbc.30122","volume":"70","author":"CJ Tan","year":"2023","unstructured":"Tan CJ, Ng ZQ, Bhattacharyya R et al (2023) Treatment and mortality of hemophagocytic lymphohistiocytosis in critically ill children: A systematic review and meta-analysis. Pediatr Blood Cancer 70:e30122. https:\/\/doi.org\/10.1002\/pbc.30122","journal-title":"Pediatr Blood Cancer"},{"key":"6847_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/jha2.57","volume":"1","author":"MC Nicholson","year":"2020","unstructured":"Nicholson MC, Naeije L, Hayden AR et al (2020) Etoposide-based treatment of adult HLH is associated with high biochemical response but poor survival outcomes. EJHaem 1:277\u2013280. https:\/\/doi.org\/10.1002\/jha2.57","journal-title":"EJHaem"},{"key":"6847_CR46","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","volume":"117","author":"A Jaccard","year":"2011","unstructured":"Jaccard A, Gachard N, Marin B et al (2011) Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study. Blood 117:1834\u20131839. https:\/\/doi.org\/10.1182\/blood-2010-09-307454","journal-title":"Blood"},{"key":"6847_CR47","doi-asserted-by":"publisher","first-page":"100206","DOI":"10.1016\/j.esmoop.2021.100206","volume":"6","author":"X Zheng","year":"2021","unstructured":"Zheng X, He X, Yang Y et al (2021) Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK\/T-cell lymphoma: a CLCG study. ESMO Open 6:100206. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100206","journal-title":"ESMO Open"},{"key":"6847_CR48","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41408-017-0021-z","volume":"7","author":"YT Tang","year":"2017","unstructured":"Tang YT, Wang D, Luo H et al (2017) Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood Cancer J 7:660. https:\/\/doi.org\/10.1038\/s41408-017-0021-z","journal-title":"Blood Cancer J"},{"key":"6847_CR49","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3892\/ol.2018.8783","volume":"16","author":"Y Chang","year":"2018","unstructured":"Chang Y, Cui M, Fu X et al (2018) Lymphoma associated hemophagocytic syndrome: A single-center retrospective study. Oncol Lett 16:1275\u20131284. https:\/\/doi.org\/10.3892\/ol.2018.8783","journal-title":"Oncol Lett"},{"key":"6847_CR50","doi-asserted-by":"publisher","first-page":"829878","DOI":"10.3389\/fimmu.2022.829878","volume":"13","author":"Z Shen","year":"2022","unstructured":"Shen Z, Jin Y, Sun Q et al (2022) A novel prognostic index model for adult hemophagocytic lymphohistiocytosis: A multicenter retrospective analysis in China. Front Immunol 13:829878. https:\/\/doi.org\/10.3389\/fimmu.2022.829878","journal-title":"Front Immunol"},{"key":"6847_CR51","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2147\/cmar.S183784","volume":"11","author":"YZ Liu","year":"2019","unstructured":"Liu YZ, Bi LQ, Chang GL et al (2019) Clinical characteristics of extranodal NK\/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. Cancer Manag Res 11:997\u20131002. https:\/\/doi.org\/10.2147\/cmar.S183784","journal-title":"Cancer Manag Res"},{"key":"6847_CR52","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00277-024-05663-6","volume":"103","author":"W Cheng","year":"2024","unstructured":"Cheng W, Xu J, Shu Y et al (2024) Association of a decreased platelet count with poor survival in patients with adult secondary hemophagocytic lymphohistiocytosis. Ann Hematol 103:1159\u20131166. https:\/\/doi.org\/10.1007\/s00277-024-05663-6","journal-title":"Ann Hematol"},{"key":"6847_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ijlh.12725","volume":"40","author":"K Nishimura","year":"2018","unstructured":"Nishimura K, Ota R, Mikajiri Y et al (2018) Useful laboratory markers for the diagnosis of bone marrow involvement by malignant lymphoma. Int J Lab Hematol 40:34\u201340. https:\/\/doi.org\/10.1111\/ijlh.12725","journal-title":"Int J Lab Hematol"},{"key":"6847_CR54","first-page":"282","volume":"29","author":"DJ Kuter","year":"2015","unstructured":"Kuter DJ (2015) Managing thrombocytopenia associated with cancer chemotherapy. Oncol (Williston Park) 29:282\u2013294","journal-title":"Oncol (Williston Park)"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06847-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06847-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06847-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:03:46Z","timestamp":1771398226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06847-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6847"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06847-y","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Affiliated Hospital of Nantong University. This study was conducted according to the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}